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Aspirin is an extremely common drug used for management of pain and inflam-
mation. Aspirin intolerance, asthma, and nasal polyps were described for the first
time by Widal and colleagues.
1 Aspirin-intolerant asthma (AIA), also known as
acetyl salicylic acid (ASA)-exacerbated respiratory disease (AERD), is a clinical
syndrome associated with severe and chronic inflammation in both upper and
lower airways resulting in chronic rhinitis, sinusitis, recurrent polyposis, and
asthma.
2 AERD presents more severe clinical symptoms and is frequently asso-
ciated with chronic eosinophilic rhinosinusitis and nasal polyposis, and occasionally
with urticaria or anaphylaxis.
2 The prevalence of aspirin hypersensitivity in the
general population ranges from 0.6 to 2.5%, and is increased in asthmatics.
3,4
AERD pathophysiology is characterized by abnormalities in the biosynthesis of
eicosanoid mediators and eicosanoid receptor expression. Increased cysteinyl
leukotrienes (LTC4, LTD4, LTE4) are potent pro-inflammatory mediators and
bronchoconstrictors in AERD pathogenesis. Therefore, AERD patients may
present more severe asthma phenotypes with irreversible airflow obstruction and
frequent exacerbation of symptoms compared to patients with aspirin-tolerant
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Aspirin intolerant asthma (AIA) is frequently characterized as an aspirin (ASA)-exacerbated respiratory disease
(AERD). It is a clinical syndrome associated with chronic severe inflammation in the upper and lower airways
resulting in chronic rhinitis, sinusitis, recurrent polyposis, and asthma. AERD generally develops secondary to
abnormalities in inflammatory mediators and arachidonic acid biosynthesis expression. Upper and lower airway
eosinophil infiltration is a key feature of AERD; however, the exact mechanisms of such chronic eosinophilic
inflammation are not fully understood. Cysteinyl leukotriene over-production may be a key factor in the induction
of eosinophilic activation. Genetic studies have suggested a role for variability of genes in disease susceptibility and
response to medication. Potential genetic biomarkers contributing to the AERD phenotype include HLA-
DPB1*301, LTC4S, ALOX5, CYSLT, PGE2, TBXA2R, TBX21, MS4A2, IL10 -1082A > G, ACE -262A > T, and
CRTH2 -466T > C; the four-locus SNP set was composed of B2ADR 46A > G, CCR3 -520T > G, CysLTR1 -634C >
T, and FCER1B -109T > C. Management of AERD is an important issue. Aspirin ingestion may result in
significant morbidity and mortality, and patients must be advised regarding aspirin risk. Leukotriene receptor
antagonists (LTRA) that inhibit leukotriene pathways have an established role in long-term AERD management
and rhinosinusitis. Aspirin desensitization may be required for the relief of upper and lower airway symptoms in
AERD patients. Future research should focus on identification of biomarkers for a comprehensive diagnostic
approach. 
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INTRODUCTIONasthma (ATA).
5
AERD is characterized by persistent and severe inflamma-
tion of the upper and lower respiratory tracts. Therefore,
the patients present with chronic eosinophilic rhinosinu-
sitis, nasal polyposis, as well as chronic persistent asthma.
The severity of asthma symptoms is usually moderate to
severe in nature, and AERD is more common in women.
The skin prick test demonstrated that a non-atopic status
was more prevalent than an atopic status in a Korean cohort
of AERD patients.
6 AERD usually begins during adulthood
and is manifested by persistent rhinitis with or without
nasal polyps.
7
Some patients have a definitive history of adverse reac-
tions to ASA and NSAIDs; however, 50% of patients in
our Korean population had not experienced adverse
reactions, suggesting that ASA challenge tests are critical
for diagnosis. Most patients demonstrated positive res-
ponses to methacholine bronchial challenge tests. The
confirmative diagnosis for AERD can be definitively
established by aspirin challenges; patients receive increas-
ing doses of oral, inhaled, or nasal lysine aspirin during
aspirin challenges. The lysine ASA bronchoprovocation
test has been widely used in Korea and Europe. It give
rapid results and a similar sensitivity to other tests.
8 Flow-
cytometric determination of aspirin-induced basophil
activation and aspirin-triggered 15-HETE generation in
peripheral blood leukocytes (PBLs) may be highly specific
and sensitive diagnostic tools;
9 however, sufficient valida-
tion is still required. In addition, further in vitro tests
including blood eosinophil levels, eosinophilic cationic
protein testing, and sputum and nasal eosinophil counts
can be measured, and are increased with symptom aggra-
vation in AERD patients.
10
AERD generally occurs due to abnormalities in mediators
and expression of arachidonic acid biosynthesis. Elevation
of Cys-LT levels in the urine, sputum, peripheral blood,
and exhaled breath were previously observed after aspirin
challenges in AERD patients.
11 AERD patients had higher
exhaled nitric oxide levels and higher baseline levels of
CysLTs in saliva, sputum, blood ex vivo and urine than
subjects with AERD.
10 Leukotriene E4 has elevated
potency relative to other CysLTs, and contributes to the
increase of histamine-induced airway responsiveness and
the enhancement of eosinophic recruitment and resultant
increases in vascular permeability, in both the lipooxyge-
nase (LOX) and cyclooxygenase (COX) pathways (Fig. 1).
12
Arachidonic acid may be metabolized through COX to
yield the prostanoids and 5-lipoxygenase (5-LO) pathway
and formation of the LTA4, LTB4 and LTC4 metabolites
upon phospholipase A2-mediated release from the cell
membrane. Hydroperoxidation of arachidonic acid is
catalyzed by 15-lipoxygenase (15-LO) to form 15-HPETE;
the other products include lipoxins (LXs) and eoxins
(EXs). Aspirin-induced inhibition of the COX pathway
leads to asthmatic attacks, shunting towards the LOX
pathway, enhanced Cys-LT production, and abnormal
regulation of the LOX pathway. This has been described in
AERD as well. Decreased lipoxin production in AERD
compared to ATA has been correlated with increased Cys-
LT. AERD may diminish LX biosynthesis capacities in
vivo after ASA challenge.
13 Cys-LTs exert effects by
binding to the Cys-LT receptors Cys-LTR1 and Cys-
LTR2.
14,15 A third receptor, GPR17, has been also identi-
fied for Cys-LTs.
16 CysLTR1 mediates airway smooth
muscle contraction, mucous hypersecretion, and microva-
scular leakage; CysLTR2 mediates inflammatory res-
ponses, potentially through the modulation of chemokine
gene transcription and contributes to vascular permeability
and tissue fibrosis.
17 Increased Cys-LTR1 expression was
detected in the nasal mucosa of patients with AERD com-
pared to ATA patients.
18 Leukotriene receptor antagonists
blocked Cys-LTR1, but did not Cys-LTR2. 
Aspirin inhibits COX-1 more frequently than COX-2,
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Fig. 1. Schematic representation of the metabolism of arachidonic acid by the
cyclooxygenase and the 5-and 15-LO pathways.and COX-2 inhibitors are usually tolerated by AERD
patients.
19 COX-2 expression was downregulated in nasal
polyps from AERD patients.
20 COX-2 was differentially
regulated in AERD patients in a recent study, and ASA
and LPS increased COX-2 expression on blood monocytes
compared to healthy subjects.
21 PGE2 is an inhibitor of
inflammatory mediator released from mast cells, eosino-
phils, and macrophages,
22 and decreased PGE2 synthesis
by nasal epithelial cells has been reported in AERD
patients
23 and may be a primary cause for AERD aggrava-
tion despite the lack of clear mechanisms. Reduced PGE2
production in airway smooth muscle cells has also been
correlated with down-regulation of COX-2 mRNA expres-
sion.
24 This suggested that PGE2 down-regulation could be
involved in AERD pathogenesis. 
Upper and lower airway eosinophil infiltration is a key
feature of AERD. Although the exact mechanisms are
unclear, cysteinyl LT over-production may induce eosino-
philic activation.
7,25 A previous study demonstrated that
serum eotaxin-2 levels were higher in the sera of AERD
patients.
26 IL-5 was increased in the nasal mucosa of
AERD patients.
27 Eoxin (EX) from the 15-LO pathway
may be a possible mechanism of eosinophil activation in
AERD patients since severe asthma and aspirin-intolerant
asthma markedly enhanced the 15-LO pathway (15-
HETE).
28,29 In addition, nasal polyps from allergic subjects
spontaneously released EXC4 in another study.
29 Multiple
polyp cell types, including eosinophils, may serve as the
EXC4 source. In addition, Staphylococcus aureus entero-
toxin (SEB) may down regulate PGE2 receptors, requiring
examination of the role SEB and other superantigens in
AERD pathogenesis. A previous study showed that
SEA/SEB specific IgE was significantly higher in AERD
patient sera than in ATA patient sera, and that patients
with high serum specific IgE to SEA had lowered PC20
methacholine, suggesting more severe airway hyperres-
ponsiveness.
30 Specific IgE to staphylococcal superan-
tigens were found in nasal polyp tissue homogenate which
closely correlated with eosinophil activation status,
31 sug-
gesting that these specific IgE response to superantigens
may be involved in upper and lower airway eosinophilic
inflammation of AERD patients.
Szczeklik hypothesized that ASA intolerant asthma
develops as the result of chronic viral infection.
32 Immun-
ological responses to infection, expressed by specific
cytotoxic lymphocytes, is under the inhibitory control of
PGE2. Cytotoxic reactions will be preceded if PGE2
removal occurs by COX inhibitor- and cytotoxic lympho-
cyte-mediated attack and destruction of virus-affected cells
of the respiratory tract. Active oxygen species, toxic meta-
bolites, and mediators released in the course of such
reactions may precipate asthma. Further, ASA sensitivity
is diminished in some AERD patients during acyclovir
treatment of herpex simplex infection.
33 IgG4 elevation
might result from chronic antigenic stimulation of viral
origin in AERD.
34
Several recent investigations have suggested that several
genetic markers may be used as AERD biomarkers (Fig. 2). 
The HLA allele DPB1*0301 may represent the AERD
phenotype, and that patients with this allele displayed
typical clinical characteristics of Samter’s triad with lowered
FEV1 levels and increased prevalence of rhinosinusitis
with nasal polyps. Further, higher doses of requirements of
leukotriene receptor antagonists was required to control
asthma symptoms, suggesting that this could serve as a
strong biomarker for an AERD phenotype.
35 
Studies have suggested that increased Cys-LT levels are
potential AERD markers. An association study demons-
trated that the C allele in the LTC4 -444A > C promoter
polymorphism was a risk factor for AERD in a Polish pop-
ulation.
36 This was not replications in other populations,
including Korean populations.
37,38
ALOX 5 is another AERD candidate, and ALOX gene
promoter polymorphism involved SP1 transcription factor
Nami Shrestha Palikhe, et al.
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Fig. 2. Genetic markers of AERD. HLA, human leukocyte antigen; LTC4S,
leukotriene C4 synthase; ALOX5, arachidonate 5-lipoxygenase; CYSLTR 1,
cysteinyl leukotriene receptor 1; CYSLTR2, cysteinyl leukotriene receptor 2;
TBXA2R, thromboxane A2 receptor; MS4A2, high affinity immunoglobulin epsilon
receptor beta-subunit; FCER1AG,high affinity immunoglobulin epsilon receptor
gamma-subunit; IL10, interleukin10; ACE, angiotensin converting enzyme-I.
GENETIC BIOMARKERS OF AERDin previous study.
39 The same polymorphism was associated
with the degree of airway hyperresponsiveness in a Korean
population.
40 No associations were noted between ALOX5-
activating protein (ALOXAP 218A > G), COX 2 (COX-2
-162C > G, 10T > C and 228G > A) and Cys-LTR1 (CYS-
LTR1 927T > C) the exon site with AERD in a Korean
population, while one ALOX5 ht1 haplotype (G-C-G-A)
was associated with AERD development.
9
Significant associations between three Cys-LTR1 SNPs
(-634C > T, -475A > C and -336A > G) and AERD were
already reported. Further, an in vitro functional study in
Jurkat T and A549 cells demonstrated increased promoter
activity in the ht2 (T-C-G) construct compared to the ht1
(C-A-A) construct, suggesting that these polymorphisms
may be important for AERD. In addition, Cys-LTR1
mRNA expression was significantly increased in vivo in
peripheral mononuclear cells when AERD patients were
exposed to aspirin.
41,42 The frequencies of several rare
CYS-LTR2 alleles (-819T > G, 2078C > T and 2534A >
G) were also higher in AERD patients than in ATA
patients.
43 These SNPs resulted in greater reduction in
FEV1 following aspirin provocation.
SNPs (n = 6) were studied in the three genes encoding
FCER1 (FCER1A, MS4A2, FCER1G). Significant
differences in the genotype frequencies of FCER1G -237A
> G were detected between AERD and ATA patients.
AERD patients carrying the homozygous AA genotype of
FCER1G -237A > G showed significantly higher total
serum IgE levels than those with the GG/AG genotype.
AERD patients carrying the CT/TT genotype at FCER1A
-344C > T showed a higher prevalence of SEA-specific
serum IgE than those with the CC genotype. The genotype
frequencies of FcepsilonR1beta-109T > C and E237G
polymorphisms were not significantly associated with
AERD pathogenesis.
44
A significant association was noted with IL10 -1082A/G
and the AERD phenotype. Further, a synergistic effect
between the TGF-β1 509C/T and IL-10 1082A/G poly-
morphisms on the AERD phenotype was noted, and when
stratified by the presence of rhinosinusitis was further
confirmed with in vitro functional assay. The IL10-1082G
reporter plasmid exhibited significantly greater promoter
activity when compared with the 1082A construct in
Jurkat T cells. Identification of the transcription factor
Myc-associated zinc-finger protein bound the 1082G allele
was reported.
45
Other markers including TBXA2R and TBX21 have
been also reported. TBXA2R +795T > C was associated
with AERD susceptibility in a Korean population.
46 Further,
the -19993T > C SNP in the TBX21 promoter region was
associated with AERD in a Japanese population.
47 These
findings were not replicated in a Korean population.
48
Another recently published study demonstrated an
association of angiotensin I-converting enzyme (ACE) gene
polymorphisms with aspirin intolerance in asthmatics. The
-262 A > T polymorphism in the ACE gene promoter is
associated with AERD, and the rare -262 A > T allele may
confer aspirin hypersensitivity via the down-regulation of
ACE expression.
49
Serum eotaxin 2 levels were related with the CRTH2
polymorphism in AERD patients. The CRTH2 -466T > C
polymorphism could increase serum and cellular eotaxin-2
production through lowered CRTH2 expression, leading to
eosinophilic infiltration in AERD patients.
26
Gene-gene interactions have been also proposed in AERD
pathogenesis, and another study demonstrated that the
genetic effects of Cys-LTR2 and LTC4S -444A > C syn-
thesis increased FEV1 lower levels after lysine -ASA
inhalation.
43 TBXA2R 795T > C was associated with HLA
DPB1*0301 in AERD patients compared with ATA.
46
Significant epistatic effects with a four-locus genetic
interaction were reported in AERD susceptibility, including
adrenergic, beta-2-receptor, B2ADR, 46A > G, chemokine
(C-C motif) receptor 3, CCR3 -520T > C, CysLTR1 -634C
> T, and FCER1B -109T > C.
50 Gene interaction with one
another resulting in AERD is still unclear.
The proper diagnosis of AERD is a challenge despite the
availability of diagnostic techniques. Genetic studies have
indicated a role for gene variability in disease susceptibility
and medication response. Potential AERD genetic bio-
markers include HLA-DPB1*301, leukotriene C4 synthase
(LTC4S), ALOX5, CYSLT, PGE2, TBXA2R, TBX21,
MS4A2, IL10 -1082A > G, ACE -262A > T, CRTH2 -466T
> C together with the four-locus SNP set B2ADR 46A >
G, CCR3 -520T > G, CysLTR1 -634C > T and FCER1B
-109T > C. Further studies evaluated these genes should
include microarray studies as well as integrative genomic,
comparative genomic and genome-wide association app-
roaches.
Aspirin ingestion may cause significant morbidity and
even mortality, and patients must be counseled accord-
ingly. Most patients can tolerate highly selective COX-2
inhibitors.
19 Acetaminophen poorly inhibits COX-1 and
COX-2, and results in rare intolerance with high-dose
exposures. A pharmacological approach based on asthma
control status should be applied.
51 Combination therapy
including inhaled corticosteroid (ICS) and long acting
beta2 agonists (LABA) may be applied with leukotriene
modifier, particularly with patients at step III or higher
levels. The ICSs inhibit eosinophils, macrophages, T-
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AERD MANAGEMENTlymphocytes, mast cells, and other inflammatory markers.
LABAs may possess anti-inflammatory properties and
may inhibit inflammatory mediator release from mast cells,
block plasma exudates, reduce airway edema, and modulate
airway sensory nerves that mediate airway hyper-respon-
siveness.
LTRAs interrupt the leukotriene pathway and have an
established role in asthma and allergic rhinitis therapy.
Two classes of leukotriene modifier drugs have been
approved for asthma treatment: the cysteinyl leukotriene 1
receptor antagonist (montelukast, zafirlukast, pranlukast)
and the 5-lipoxygenase (5-LO) inhibitor. Both have been
widely prescribed for symptom control in both upper and
lower airway of AERD patients.
52,53 Several pharmaco-
genetic LTRA studies have been reported which consider
the genetic polymorphisms of CYSLTR1.
53 Our previous
data have suggested that patients carrying the T allele at
CYSLTR1 at -634 C > T required higher doses of cysLTR1
antagonists to control their asthmatic symptoms.
42
Improvement of aspirin intolerance is essential for success-
ful management of chronic rhinosinusitis. Nasal deconges-
tants and antihistamines are used but provide transient
relief. Topical corticosteroids are effective in most AERD
patients with rhinosinusitis.
54 Several reports have sug-
gested that LTRA could improve rhinosinusitis and nasal
polyps without surgery,
55,56 suggesting that endoscopic
nasal surgery should be selected for severe chronic sinusitis
with multiple nasal polyps and nasal passage obstruction.
Aspirin desensitization can be beneficial for some AERD
patients with upper and lower airway inflammation;
however, it is recommended for AERD patients with corti-
costeroid-dependent asthma or those requiring daily
ASA/NSAID therapy for other medical diseases including
coronary artery disease or chronic arthritis. Oral adminis-
tration with an initial desensitization with incremental
doses of aspirin followed by daily high dose therapy may
be safe and clinically effective, and may produced definite
improvements in both upper and lower respiratory tract
symptoms in the majority of patients with aspirin sensiti-
vity.
57 The regimen contains escalating doses of oral
aspirin over two to five days until 650 mg can be tolerated
twice daily. Aspirin can be reduced after symptom impro-
vement. The precise mechanism by desensitization in
aspirin intolerance therapy is unclear. However, leuko-
triene B4 and thromboxane B4 were reduced in a cell
culture model and were similar to normal controls after
aspirin desensitization.
58 Another study demonstrated
decreased bronchial responsiveness to inhaled leukotriene
E4 on the first day of sensitization therapy.
59 Direct modul-
ation of intracellular biochemical pathways of inflamma-
tory cells could serve as another possible mechanism.
Future areas of investigation should focus on identification
of biomarkers for early diagnosis with various diagnostic
techniques. AERD has heterogenous phenotypes, and this
impairs current diagnostic techniques and there are no
current animal models. Increased comprehensions of the
molecular, cellular, and biochemical basis of AERD will
be helpful for the determination of new diagnostic tools
and therapeutic interventions. 
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